Glycosylated hemoglobin and the degree of sarcopenia: a systematic review

Abstract

Introduction: Type II diabetes mellitus (DM2) and sarcopenia are conditions that present a high prevalence and significant complications, which makes them important public health problems. Objectives: To conduct a systematic review on the clinical correlation of glycosylated hemoglobin and the degree of sarcopenia in patients with type II diabetes mellitus for its correct diagnosis and management in our environment. Methodology: This study is based on a systematic review of 12 original scientific articles published between January 2019 and June 2023, focused on the relationship between DM2 and sarcopenia. Results: The findings indicate an increasing prevalence of sarcopenia in patients with T2DM, especially when glycemic control is inadequate. It was observed that glycosylated hemoglobin (HbA1c) levels greater than 8.5% are associated with an increased risk of developing sarcopenia. The studies analyzed also suggest that the most effective treatment to mitigate sarcopenia is a combination of resistance exercise and nutritional counseling. Although HbA1c is a useful indicator for monitoring glycemic control, it does not reflect daily fluctuations in glucose levels, which are also a crucial factor in the development of sarcopenia. Conclusions: The review concludes that early diagnosis and multidisciplinary intervention are crucial to prevent and treat sarcopenia in patients with T2DM. General area of study: Health. Specific area of study: General Medicine. Type of study:  Original articles